In the bustling city of Abu Dhabi, a new player has emerged in the investment landscape - M42. Formed through the amalgamation of the healthcare assets of two prominent Abu Dhabi investment firms, M42 has set its sights on becoming a formidable force in the realm of healthcare, powered by artificial intelligence. Chief Executive Officer Hasan Jasem Al Nowais reveals that the company is actively pursuing about 50 potential deals each month, strategically seeking opportunities that align with their vision for the future.
Last year, M42 made a significant move with the acquisition of Diaverum, a major dialysis clinic operator in Europe, for approximately $2.5 billion. Buoyed by this success, Al Nowais shares the company's ambitious plans for expansion into Europe, Latin America, and Asia. With a keen focus on leveraging Abu Dhabi's technological prowess, M42 aims to integrate AI into healthcare services for enhanced diagnostics and drug discovery.
In a world where global healthcare spending continues to rise, M42 recognizes the pressing need to address escalating health costs. Al Nowais emphasizes the pivotal role of technology in curbing these expenses, stating, "There is no other way than technology." M42's approach is underpinned by a commitment to harnessing AI to revolutionize healthcare delivery and contain costs.
Backed by Mubadala and G42, M42 enjoys robust support from these heavyweight investors, enabling the company to pursue its growth trajectory boldly. Al Nowais praises the strategic advantage of having two formidable entities as parents, emphasizing their unwavering support for M42's endeavors.
Additionally, the company's collaboration with G42, a prominent AI firm in the Middle East, amplifies its capabilities in the technology arena. Anchored by Sheikh Tahnoon's leadership, G42's influence and resources bolster M42's quest to innovate in healthcare through AI-driven solutions.
M42's pioneering projects, such as the Emirati Genome Programme, epitomize its commitment to leveraging cutting-edge technology for the betterment of healthcare. By assembling a vast DNA database and employing AI algorithms, M42 aims to deliver personalized treatment regimens based on individual genetic profiles. This personalized approach holds the promise of enhancing patient care and treatment outcomes.
Moreover, M42's initiatives in AI-powered drug discovery and tuberculosis screening underscore its dedication to advancing healthcare on a global scale. By piloting innovations in Abu Dhabi and scaling them worldwide, M42 is poised to make a lasting impact on the healthcare landscape.
Al Nowais emphasizes that M42's mission transcends mere financial gains, with a primary focus on creating meaningful impact for humanity. By prioritizing impactful solutions and technological advancements, M42 aims to shape the future of healthcare and drive positive change worldwide.